Cyclooxygenase inhibition and cardiovascular risk

被引：205

作者：

Antman, EM

DeMets, D

Loscalzo, J

机构：

[1] Brigham & Womens Hosp, Div Cardiovasc, Dept Med, Boston, MA 02115 USA

[2] Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI USA

来源：

CIRCULATION | 2005年 / 112卷 / 05期

关键词：

inflammation; pharmacology; platelets; prostaglandins; thromboxane;

D O I：

10.1161/CIRCULATIONAHA.105.568451

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：759 / 770

页数：12

共 88 条

[1] Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure [J].

Aw, TJ ;

Haas, SJ ;

Liew, D ;

Krum, H .

ARCHIVES OF INTERNAL MEDICINE, 2005, 165 (05) :490-496

[2] Endothelial cell activation by endotoxin involves superoxide/NO-mediated nitration of prostacyclin synthase and thromboxane receptor stimulation [J].

Bachschmid, M ;

Thurau, S ;

Zou, MH ;

Ullrich, V .

FASEB JOURNAL, 2003, 17 (03) :914-+

[3]

Belton O, 2000, CIRCULATION, V102, P840

[4] The Rresearch on Adverse Drug Events and Reports (RADAR) project [J].

Bennett, CL ;

Nebeker, JR ;

Lyons, EA ;

Samore, MH ;

Feldman, MD ;

McKoy, JM ;

Carson, KR ;

Belknap, SM ;

Trifilio, SM ;

Schumock, GT ;

Yarnold, PR ;

Davidson, CJ ;

Evens, AM ;

Kuzel, TM ;

Parada, JP ;

Cournoyer, D ;

West, DP ;

Sartor, O ;

Tallman, MS ;

Raisch, DW .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 293 (17) :2131-2140

[5] The use of nonsteroidal anti-inflammatory drugs (NSAIDs) - A science advisory from the American Heart Association [J].

Bennett, JS ;

Daugherty, A ;

Herrington, D ;

Greenland, P ;

Roberts, H ;

Taubert, KA .

CIRCULATION, 2005, 111 (13) :1713-1716

[6] Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning [J].

Bolli, R ;

Shinmura, K ;

Tang, XL ;

Kodani, E ;

Xuan, YT ;

Guo, YR ;

Dawn, B .

CARDIOVASCULAR RESEARCH, 2002, 55 (03) :506-519

[7] Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. [J].

Bombardier, C ;

Laine, L ;

Reicin, A ;

Shapiro, D ;

Burgos-Vargas, R ;

Davis, B ;

Day, R ;

Ferraz, MB ;

Hawkey, CJ ;

Hochberg, MC ;

Kvien, TK ;

Schnitzer, TJ ;

Weaver, A .

NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (21) :1520-1528

[8] Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial [J].

Bresalier, RS ;

Sandler, RS ;

Quan, H ;

Bolognese, JA ;

Oxenius, B ;

Horgan, K ;

Lines, C ;

Riddell, R ;

Morton, D ;

Lanas, A ;

Konstam, MA ;

Baron, JA .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (11) :1092-1102

[9]

BROPHY J, 2005, HOT TOPIC CYCLOOXYGE

[10] Selective cyclo-oxygenase-2 inhibition with parecoxib acutely impairs endothelium-dependent vasodilatation in patients with essential hypertension [J].

Bulut, D ;

Liaghat, S ;

Hanefeld, C ;

Koll, R ;

Miebach, T ;

Mügge, A .

JOURNAL OF HYPERTENSION, 2003, 21 (09) :1663-1667

← 1 2 3 4 5 6 7 8 9 →